Tiejun Qin

chinese academy of medical sciences - peking union medical college

H指数:20

被引数:1,261

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The role of CD38 in monocytes during fibrotic progression of myeloproliferative neoplasms

CD38在骨髓增殖性肿瘤纤维化进展期间单核细胞中的作用

Blood

IF23.1

2026-02-261

PRE

The prognostic impact of chromosome 7 with both arms loss [der(7)del(7p)del(7q)] in myelodysplastic syndrome/neoplasm

染色体7双臂缺失[der(7)del(7p)del(7q)]在骨髓增生异常综合征/肿瘤中的预后影响

Hematology

IF1.6

2025-12-310

PRE

The dynamic alterations of DDX41 mutations in patients with myelodysplastic neoplasms treated with lenalidomide

接受来那度胺治疗的骨髓增生异常性肿瘤患者中DDX41突变的动态变化

LEUKEMIA & LYMPHOMA

IF2.2

2025-11-010

PRE

Aberrant splicing of CHEK1 is a driver of megakaryocytic dysplasia in U2AF1S34F mutant myelodysplastic neoplasms

CHEK1的异常剪接是U2AF1S34F突变骨髓增生异常新生物中巨核细胞发育不良的驱动因素。

Leukemia

IF13.4

2025-07-120

PRE

A correlation of ineffective erythropoiesis and dysregulated signaling pathways in myelodysplastic syndromes/neoplasms

骨髓增生异常综合征/肿瘤中无效性红细胞生成和信号通路失调的相关性

hematology oncology

IF13.5

2025-05-140

GATA1 insufficiencies in dysmegakaryopoiesis of myelodysplastic syndromes/neoplasms

MDS/MPN中异常巨核细胞生成的GATA1不足

PATHOLOGY RESEARCH AND PRACTICE

IF3.2

2025-05-010

PRE

The Molecular Features of Chronic Eosinophilic Leukemia, Not Otherwise Specified

慢性嗜酸性粒细胞白血病，非其他特指的分子特征

AMERICAN JOURNAL OF HEMATOLOGY

IF9.9

2025-02-250

PRE

GATAI Insufficiencies in Dysmegakaryopoiesis of Myelodysplastic Syndromes/Neoplasms

GATAI 在骨髓增生异常综合征/肿瘤中的巨核细胞发育异常不足

BLOOD

IF23.1

2024-11-050

PRE

Predicting survival in patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis

LEUKEMIA

IF13.4

2024-05-070

OAAI

Gadd45g insufficiency drives the pathogenesis of myeloproliferative neoplasms

Gadd45g功能不全驱动骨髓增殖性肿瘤的发病机制

NATURE COMMUNICATIONS

IF15.7

2024-04-061

OAAI

Non-driver mutations landscape in different stages of primary myelofibrosis determined ASXL1 mutations play a critical role in disease progression

BLOOD CANCER JOURNAL

IF11.6

2023-04-203

OAAI

Distinguishing myelodysplastic syndromes with moderate-to-severe bone marrow fibrosis from triple-negative primary myelofibrosis based on clinical and genetic covariates

HEMATOLOGICAL ONCOLOGY

IF3.9

2022-10-270

PRE

IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons ≥ 60 years with myelodysplastic syndromes

hematology oncology

IF13.5

2022-10-1720

OAAI

Comparison of the revised 4th (2016) and 5th (2022) editions of the World Health Organization classification of myelodysplastic neoplasms

LEUKEMIA

IF13.4

2022-10-1225

OAAI

ASXL1 mutations accelerate bone marrow fibrosis via EGR1-TNFA axis-mediated neoplastic fibrocyte generation in myeloproliferative neoplasms

HAEMATOLOGICA

IF7.9

2022-08-2512

OAAI

Ruxolitinib combined with prednisone, thalidomide and danazol in patients with myelofibrosis: Results of a pilot study

HEMATOLOGICAL ONCOLOGY

IF3.9

2022-05-288

PRE

Myelodysplastic syndromes are multiclonal diseases derived from hematopoietic stem and progenitor cells

骨髓增生异常综合征是源自造血干细胞和祖细胞的多系疾病

hematology oncology

IF13.5

2022-05-160

OAAI

Conventional interferon-α 2b versus hydroxyurea for newly-diagnosed patients with polycythemia vera in a real world setting: a retrospective study based on 286 patients from a single center

HAEMATOLOGICA

IF7.9

2022-01-066

OAAI

Iron deficiency in JAK2 exon12 and JAK2-V617F mutated polycythemia vera

BLOOD CANCER JOURNAL

IF11.6

2021-09-177

OAAI

RBC distribution width predicts thrombosis risk in polycythemia vera

LEUKEMIA

IF13.4

2021-09-0811

OAAI

Tiejun Qin

个人简介

教育背景

工作经历

荣誉奖项

研究方向